Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
17.78 -1.21 (-6.37%) 03/07/25 [NASDAQ]
17.71 x 100 18.55 x 300
Realtime by (Cboe BZX)
17.71 x 100 18.55 x 300
Realtime 17.69 -0.09 (-0.51%) 06:25 ET
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.70
Day High
18.97
Open 18.86
Previous Close 18.99 18.99
Volume 3,410,100 3,410,100
Avg Vol 2,678,775 2,678,775
Stochastic %K 16.56% 16.56%
Weighted Alpha -16.34 -16.34
5-Day Change -2.91 (-14.06%) -2.91 (-14.06%)
52-Week Range 2.10 - 33.89 2.10 - 33.89
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,115,951
  • Shares Outstanding, K 737,680
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -226 M
  • EBITDA $ -226 M
  • 60-Month Beta -1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 36.02

Options Overview Details

View History
  • Implied Volatility 104.07% ( +4.85%)
  • Historical Volatility 87.71%
  • IV Percentile 38%
  • IV Rank 15.18%
  • IV High 262.57% on 04/09/24
  • IV Low 75.71% on 06/28/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 2,699
  • Volume Avg (30-Day) 4,466
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 80,833
  • Open Int (30-Day) 70,565

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.70 +0.45%
on 03/07/25
Period Open: 20.11
24.18 -26.47%
on 02/21/25
-2.33 (-11.59%)
since 02/07/25
3-Month
16.46 +8.02%
on 01/14/25
Period Open: 18.54
25.00 -28.88%
on 01/24/25
-0.76 (-4.10%)
since 12/06/24
52-Week
2.10 +746.67%
on 05/28/24
Period Open: 4.72
33.89 -47.54%
on 09/16/24
+13.06 (+276.69%)
since 03/07/24

Most Recent Stories

More News
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and provided a disappointing guidance for 2025.On Feb. 4, Merck announced its...

JNJ : 166.69 (+0.52%)
MRK : 94.65 (+0.69%)
SMMT : 17.78 (-6.37%)
MRNA : 35.61 (+3.82%)
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer

Summit Therapeutics SMMT reported fourth-quarter 2024 loss per share of 8 cents, in line with the Zacks Consensus Estimate. In the year-ago period, the company incurred a loss of 5 cents per share.The...

MRK : 94.65 (+0.69%)
SMMT : 17.78 (-6.37%)
PFE : 26.73 (+1.87%)
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

VXF : 178.94 (+0.26%)
SMMT : 17.78 (-6.37%)
VTI : 283.34 (+0.47%)
PFE : 26.73 (+1.87%)
IWM : 205.95 (+0.33%)
3 Stocks That Could Trounce the Market in 2025

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

SMMT : 17.78 (-6.37%)
LLY : 869.58 (-4.73%)
VRTX : 488.29 (+0.53%)
Is Summit Therapeutics a Millionaire Maker?

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT) . The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress...

SMMT : 17.78 (-6.37%)
2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) . Both saw their shares more than...

VKTX : 29.10 (+1.46%)
SMMT : 17.78 (-6.37%)
LLY : 869.58 (-4.73%)
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?

It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate,...

SMMT : 17.78 (-6.37%)
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how analysts view a given stock. After all, their opinions are (or at least, should...

NVO : 87.17 (-0.99%)
MRK : 94.65 (+0.69%)
SMMT : 17.78 (-6.37%)
BEPC : 27.67 (+2.63%)
BEP : 22.51 (+2.60%)
Why Summit Therapeutics Stock Is Jumping Today

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for the...

SMMT : 17.78 (-6.37%)
MRK : 94.65 (+0.69%)
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?

Key TakeawaysMerck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia.Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly...

MRK : 94.65 (+0.69%)
SMMT : 17.78 (-6.37%)
EXEL : 38.58 (+0.97%)
MRNA : 35.61 (+3.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 19.87
2nd Resistance Point 19.42
1st Resistance Point 18.60
Last Price 17.78
1st Support Level 17.33
2nd Support Level 16.88
3rd Support Level 16.06

See More

52-Week High 33.89
Fibonacci 61.8% 21.75
Fibonacci 50% 17.99
Last Price 17.78
Fibonacci 38.2% 14.24
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights